Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma (pages 2141–2148)
James R. Berenson, Sundar Jagannath, Bart Barlogie, David T. Siegel, Raymond Alexanian, Paul G. Richardson, David Irwin, Melissa Alsina, S. Vincent Rajkumar, Gordon Srkalovic, Seema Singhal, Steven Limentani, Ruben Niesvizky, Dixie L. Esseltine, Elizabeth Trehu, David P. Schenkein and Kenneth Anderson
Article first published online: 4 OCT 2005 | DOI: 10.1002/cncr.21427
Bortezomib therapy beyond 8 cycles (6 mos) was safe and tolerable in patients with relapsed, refractory myeloma who had benefited from therapy in the SUMMIT and CREST Phase II clinical trials. These 63 patients were able to receive an additional median 7 cycles (approximately 5 mos) of therapy at a mean dose intensity identical to that of the parent protocol.